Figure 6.
Figure 6. Flow cytometric analysis of spleen of AMN107- and placebo-treated mice. Flow cytometry of spleen cells from mice with TEL-PDGFRβ (A,C) or FIP1L1-PDGFRα (B,D) disease treated with placebo (left) or AMN107 (right). Cells were stained with Gr-1 and Mac-1 for myeloid cells (A-B) or B220 and CD19 for B lymphoid cells (C-D). A total of 10 000 events were recorded from the population of cells that was both viable (based on forward and side scatter and on absence of 7AAD staining) and GFP+. Representative dot plots from 1 of 2 mice analyzed are shown; below the plots are the percentages of cells in each quadrant.

Flow cytometric analysis of spleen of AMN107- and placebo-treated mice. Flow cytometry of spleen cells from mice with TEL-PDGFRβ (A,C) or FIP1L1-PDGFRα (B,D) disease treated with placebo (left) or AMN107 (right). Cells were stained with Gr-1 and Mac-1 for myeloid cells (A-B) or B220 and CD19 for B lymphoid cells (C-D). A total of 10 000 events were recorded from the population of cells that was both viable (based on forward and side scatter and on absence of 7AAD staining) and GFP+. Representative dot plots from 1 of 2 mice analyzed are shown; below the plots are the percentages of cells in each quadrant.

Close Modal

or Create an Account

Close Modal
Close Modal